Hjem › Plasmacellekreft › Massachusetts
Kliniske studier for Plasmacellekreft i Massachusetts
5 studier for Plasmacellekreft søker deltakere på steder i Massachusetts.
Byer i Massachusetts
Offisiell studietekst (engelsk)
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Beth Israel Deaconess Medical Center, Boston
- BIDMC Research Pharmacy, Boston
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 24. aug. 2026 · NCT06152575A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT05651932Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT07426484Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. des. 2025 · NCT06518551HEME Home Transfusion Program
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2025 · NCT06487247Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.